Data and technology for cancer care
Edinburgh Cancer Informatics are part of a large partnership of Universities and learning centres from across Europe, taking part in a mass data standardisation programme to investigate cancer survival rates from date of diagnosis. The aim of this European-wide project is to examine the incidence, and survival of certain cancers to see how well mathematical […]
A huge congratulations are in order to Professor Peter Hall and Doctor Mahéva Vallet, who have both had work published in the journal ‘The Breast’, this week. An abstract of the paper, entitled “Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective” can be found below. The Oncotype DX Breast RS test has […]
As seen at the CRUK Data Conference ’24 Estimation of prognosis is vital for informing decisions around care and its value, especially in patients with poor prognosis cancer (PPC) where there is a risk of under- or over-treatment. Established risk stratification tools can be derived from routine healthcare records, allowing population-level research. A well-used example […]
Lung cancer is the most common cause of cancer death in the UK. Our study aims to assess whether early prehabilitation is feasible in these patients. Many patients aren’t fit for anticancer treatment, due to a combination of burden of disease, patient fitness and comorbidities. These issues affect energy levels and performance status, which results […]
Innovative new medicines used in conjunction with neoadjuvant chemotherapy (NACT) may lead to a higher pathological complete response (pCR), and therefore a better chance of survival for patients diagnosed with eTNBC cancer. The Edinburgh Cancer Informatics, in partnership with DATA-CAN, ran a retrospective, longitudinal cohort study using routinely collected data to better describe differences in […]
Collaboration with the Edinburgh Cancer Informatics team enabled an investigation of the Real-World Impact of stereotactic ablative body radiotherapy (SABR) along with other conventional methods (conventional radiotherapy and surgery) on Stage I Non-Small-Cell Lung Cancer (NSCLC) patients in South-East Scotland. A total of 1143 patients discussed at MDM between January 2012 and December 2019 were selected for this study from the Edinburgh Cancer Centre Lung […]
Brain Tumour Pathway – a REDCap Project Critical to accelerating the discovery of new therapies for brain tumours and their translation into the clinic, is to investigate diagnosis, treatment and outcomes at a population level, mapping this to molecular interrogation of resected tumour tissue, and liquid biopsies from patients. In collaboration with researchers at […]
This Data Linkage study exploits historically strong maternity and cancer registration data in Scotland to produce more evidence to help women in their decision making on pregnancy after treatment for early breast cancer. The impact of childbirth on survival after breast cancer remains controversial. National cancer and birth data were used to analyse an unbiased […]
Disparities in breast cancer care quality have reduced Regional variation in chemotherapy treatment for breast cancer across Scotland has reduced significantly over the past 15 years, according to a new study: December 2021 The findings suggest that there is now limited inequalities in treatment across the majority of the country’s 14 health boards. Experts from […]
Edinburgh was one of eight cancer centres from accross the world that was able to contribute real world data to a pooled analysis that validated RCB as a strong predictor in all breast cancer subtypes.
